tbuckley/cabot-search huggingface dataset:
High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients.
Authors: Rainer Vormittag, Christine Marosi, Cihan Ay, Ralph Simanek, Ilse Schwarzinger, Matthias Preusser, Katarzyna Elandt, Christoph C Zielinski, Ingrid Pabinger
Journal: Blood (2009)
Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity
Authors: Christina Krupka, Thomas Köhnke, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, Marion S. Subklewe
Journal: Blood (2015)
Abstract P3-13-28: Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection
Authors: L Vandermeeren, J-P Belgrado, S Vankerckhove, J-B Valsamis, V Feipel, M Rooze, J-J Moraine, D Hertens, B Carly, F Liebens
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Endoscopic ampullectomy: to inject or not to inject? The underwater technique
Authors: Antonino Granata, Gabriele Curcio, Dario Ligresti, Luca Barresi, Ilaria Tarantino, Rosa Liotta, Mario Traina
Journal: Endoscopy (2014)

Correction to: Endoscopic ampullectomy: to inject or not to inject? The underwater techniqueEndoscopy 2014; 46(S 01): E478-E479DOI: 10.1055/s-0034-1377538
Abstract MP006: A Feasible and Effective Mobile Health Weight Loss Lifestyle Intervention for Filipinos With Type 2 Diabetes
Authors: Melinda S Bender, Bruce Cooper, Shoshana Arai
Journal: Circulation (2017)

Introduction: Filipino Americans have the highest prevalence of obesity and type 2 diabetes (T2D) compared to Asian American subgroups placing them at high risk for cardiometabolic disease. Effective interventions are needed to reduce these health disparities. Mobile health (mHealth) weight loss lifestyle interventions have been effective in reducing cardiometabolic risks, but are untested among Filipinos, particularly with T2D. As prolific users of digital technology, Filipinos are ideal candidates for mHealth lifestyle interventions. Therefore, we conducted the PilAm Go4Health intervention study - a culturally adapted weight loss lifestyle intervention using mobile technology to reduce cardiometabolic risks among Filipinos with T2D. Objective: To demonstrate intervention feasibility and potential efficacy. Hypothesis: 1) participant retention rate will be greater than 80%; 2) Compared to the control, intervention group will have significantly greater reduction in: % weight loss, waist circumference, fasting plasma glucose, and HbA1; and greater increase in step-counts. Methods: Two-arm (intervention +active control groups) RCT compared a 3-month intervention (Fitbit accelerometer +mHealth app/diary +Facebook group) and control (Fitbit accelerometer). N=45 overweight Filipino adults with T2D were recruited from Northern California communities. Between group differences from baseline to 3-months were analyzed using: 1) multilevel regression for within-person change in weight and step-counts using a nonparametric bias-corrected bootstrapped 95% CI for the multilevel models, and 2) T-tests, ANOVA for waist circumference, fasting plasma glucose, and HbA1c (significance =p&lt;0.05, 2-sided). Cohen’s d was used for effect size analyses. Results: Randomized N=45 Filipinos (intervention =22 and control =23). Mean age was 58±10 years, 62% women, and retention rate=100%. There was significantly greater reduction in the intervention group compared to the control for: % weight (2.3% greater decrease, d=0.46); waist circumference (-2.68cm; d= 0.88); and fasting plasma glucose (-18.52mg/dl; d= -0.86). HbA1c group difference was not significant (-0.34%; p&lt; 0.19). Step-counts significantly increased in the intervention group compared to control (3432 steps at endpoint; d=1.44). Conclusion: PilAm Go4Health intervention demonstrated excellent feasibility in recruitment and retention, and potential efficacy for reducing cardiometabolic risks in Filipinos with T2D. Results warrant further testing of this lifestyle intervention that may support translation to other at-risk diverse populations living with T2D.
Dementia incidence trend over 1992-2014 in the Netherlands: Analysis of primary care data
Authors: Emma F. van Bussel, Edo Richard, Derk L. Arts, Astrid C. J. Nooyens, Preciosa M. Coloma, Margot W. M. de Waal, Marjan van den Akker, Marion C. J. Biermans, Markus M. J. Nielen, Kees van Boven, Hugo Smeets, Fiona E. Matthews, Carol Brayne, Wim B. Busschers, Willem A. van Gool, Eric P. Moll van Charante
Journal: PLoS Medicine (2017)

Recent reports have suggested declining age-specific incidence rates of dementia in high-income countries over time. Improved education and cardiovascular health in early age have been suggested to be bringing about this effect. The aim of this study was to estimate the age-specific dementia incidence trend in primary care records from a large population in the Netherlands.A dynamic cohort representative of the Dutch population was composed using primary care records from general practice registration networks (GPRNs) across the country. Data regarding dementia incidence were obtained using general-practitioner-recorded diagnosis of dementia within the electronic health records. Age-specific dementia incidence rates were calculated for all persons aged 60 y and over; negative binomial regression analysis was used to estimate the time trend. Nine out of eleven GPRNs provided data on more than 800,000 older people for the years 1992 to 2014, corresponding to over 4 million person-years and 23,186 incident dementia cases. The annual growth in dementia incidence rate was estimated to be 2.1% (95% CI 0.5% to 3.8%), and incidence rates were 1.08 (95% CI 1.04 to 1.13) times higher for women compared to men. Despite their relatively low numbers of person-years, the highest age groups contributed most to the increasing trend. There was no significant overall change in incidence rates since the start of a national dementia program in 2003 (-0.025; 95% CI -0.062 to 0.011). Increased awareness of dementia by patients and doctors in more recent years may have influenced dementia diagnosis by general practitioners in electronic health records, and needs to be taken into account when interpreting the data.Within the clinical records of a large, representative sample of the Dutch population, we found no evidence for a declining incidence trend of dementia in the Netherlands. This could indicate true stability in incidence rates, or a balance between increased detection and a true reduction. Irrespective of the exact rates and mechanisms underlying these findings, they illustrate that the burden of work for physicians and nurses in general practice associated with newly diagnosed dementia has not been subject to substantial change in the past two decades. Hence, with the ageing of Western societies, we still need to anticipate a dramatic absolute increase in dementia occurrence over the years to come.
Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial
Authors: Katja Sockel, Jochen Greiner, Rudolf Trenschel, Christian Unzicker, Guido Kobbe, Jürgen Finke, Ulrich Germing, Brigitte Mohr, Dietrich Beelen, Gerhard Ehninger, Martin Bornhaeuser, Uwe Platzbecker
Journal: Blood (2011)
Safety and Efficacy of Enzyme Replacement Therapy (ERT) in Combination with Haematopoietic Stem Cell Transplantation (HSCT) for Hurler’s Syndrome: European Experience 2003–2005.
Authors: Jaap Jan Boelens, R. Wynn, E. Wraith, A. O’Mearra, P. Veys, N. Wulffraat
Journal: Blood (2005)
The Outcome of Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukaemia: A Single Centre 10-Year-Experience
Authors: Patrycja Zielinska, Malgorzata Krawczyk-Kulis, Miroslaw Markiewicz, Monika Dzierzak-Mietla, Anna Koclega, Robert Liwoch, Anna Kopinska, Slawomira Kyrcz-Krzemien
Journal: Blood (2011)
Retroviral Gene Therapy of RAG-1-/- Mice: Balance between Efficiency and Toxicity.
Authors: Chantal Lagresle-Peyrou, Frank Yates, Michele Malassis-Seris, Christophe Hue, Estelle Morillon, Alexandrine Garrigue, Allen Liu, Philippe Hajdari, Daniel Stockholm, Olivier Danos, Brigitte Lemercier, Marie-Lize Gougeon, Frederic Rieux-laucat, Jean-Pierre de Villartay, Alain Fischer, Marina Cavazzana-Calvo
Journal: Blood (2005)
BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab
Authors: Sarah Huet, Edith Szafer‐Glusman, Bruno Tesson, Luc Xerri, Wayne J. Fairbrother, Kiran Mukhyala, Chris Bolen, Elizabeth Punnoose, Laurie Tonon, Catherine Chassagne‐Clément, Pierre Feugier, Alain Viari, Fabrice Jardin, Gilles Salles, Pierre Sujobert
Journal: American Journal of Hematology (2017)

Abstract BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab‐containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA‐targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over‐activation of AICDA (activation‐induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N‐terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow‐up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression‐free survival.
Whole Exome Sequencing Reveals That DNMT3A and ASXL1 Mutation Are Involved in the Development of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Patients without ABL1 Tyrosine Kinase Domain Mutation
Authors: Taehyung Simon Kim, Zhaolei Zhang, Marc Tyndel, Jae-Sook Ahn, Seunghyun Choi, Hyeoung Joon Kim, Jeffrey H. Lipton, Dennis Dong Hwan Kim
Journal: Blood (2015)
IL-21 Promotes Apoptosis through Induction of the BH3 Only Protein Bim and Enhacnes Direct and Innate Immune-Promoted Death of Chronic Lymphocytic Leukemia Cells.
Authors: Julie M. Roda, Aruna Gowda, Rehan Hussain, Asha Ramanunni, Amy Lehman, Wayne Kindsvogel, William E. Carson, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2007)
PD1/PDL-1 and VEGF expression in lymph node microenvironment and relation with tumor burden and survival in cutaneous melanomas.
Authors: Vinicius L Vazquez, Cristiano Viana, Cristovam Scapulatempo, Sergio Vicente Serrano, Cristina Alessi
Journal: Journal of Clinical Oncology (2015)

9026 Background: The regional lymph nodes are the most common site for melanoma metastasis. The understanding of lymph node microenvironment may lead to the comprehension of the metastasis development and factors related to tumour progression. The aims of this study are to characterize the PD1 (programmed cell death-1), VEGF (Vascular endothelial growth factor) A and C expression in the regional lymph nodes of melanoma patients with and without metastasis; PDL-1 (PD1 ligand) in the lymph node metastasis; and their relation to tumour burden and survival. Methods: We retrospectively researched the sentinel nodes, both negative, (pn0) positive (pN1+), and the negative nodes retrieved from the lymph node dissection of the sentinel positive patients (pN1-); Immunohistochemistry was performed looking for the expression of PD-1, VEGFA and C in the lymph node normal/surrounding tumor tissue and their correlation to clinical findings. Results: 20 negative sentinel lymph nodes (pN0), 20 positive sentinel nodes (pN1+) and 18 negative lymph nodes from patients with lymph node metastasis (pN1-) were analysed. Follow up ranged from 5.91 to 85.45 months; mean 38.77 (SD 16.13). PD-1 was expressed in 94.7% of pN0, 77.8% of pN1- and 47.1% of pN1+ (p = 0.006). PDL-1 was expressed in 68.7% of the tumor cases. VEGF A was expressed in 6.7% of pN0, 16.7% of pN1- and 72,2% of pN1+ (p < 0.001). VEGF C expression was present in 89.5% of pN0, 55.6% of pN1- and 80% of pN1+ (p = 0.101). Five years survival of PD1 negative patients was 42.9% and PD1 positive 77.1% (p = 0.034). PDL1 (only N1+) Five years survival was 33.3% in positive cases versus 24.2% in negative ones (p = 0.566). VEGF A five years survival was 78.4% for negative cases and 43.4% for positive ones (p = 0.008). VEGF C was 68.6% for negative cases and 66.9% for positive (p = 0.746) Conclusions: PD-1 expression in the regional lymph node is associated to absence or low tumour burden what is related to higher survival rates. VEGFA expression in the regional lymph node is associated to presence or high tumour burden what is related to low survival. Further studies should be performed to confirm this data and look at their clinical implications. Supported by CNPQ grant #447590/2014-6
CD160 Expression in B-Cell Lymphoproliferative Disorders: Derivation and Validation of a New Three-Antigen Scoring System Improving Diagnostic Precision in B-Cell Malignancies.
Authors: Timothy W Farren, Feng-Ting Liu, Claire Stephens, Dimitris Tsitsikas, Marion G Macey, Michael Jenner, John G. Gribben, Samir G Agrawal
Journal: Blood (2009)
Presence of Bcr-Abl Positive Cells in Peripheral Blood Leukocytes of Immunosuppressed Solid Organ Transplant (SOT) Recipients
Authors: Philipp D. le Coutre, Petra Reinke, Ruth Neuhaus, Ralf Trappe, Frauke Ringel, Philipp Hemmati, Bernd Dörken, Peter Daniel
Journal: Blood (2008)
Prospetive study of thalidomide maintenance therapy in high-risk diffuse large B-cell lymphoma.
Authors: He Huang, Tongyu Lin, Xiaoting Lin, Chaoyong Liang, Chengcheng Guo, Huangming Hong, Ying Tian, Tingzhi Liu, Mengping Zhang, Xueying Li, Xiaohong Fu, Zhao Wang, Xiaojie Fang, Shanshan Li, Jian Xiao, Yabing Cao
Journal: Journal of Clinical Oncology (2014)

e19551 Background: Patients with high-risk diffuse large B-Cell lymphoma (DLBCL) have a unfavourable clinical outcome even treated with R-CHOP. Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities.This study aimed to explore the efficacy and the tolerability of thalidomide maintenance treatment in patients with high-risk DLBCL. Methods: Patients diagnosised as DLBCL with IPI≥2, aged ≥18 year-old, who achieved completed remission after induction therapy ,with full liver , kidney and bone-marrow function, were eligible for this study. Patients were assigned to receive thalidomide (100 mg/day, increased by 100 mg every 3 days to a maximum of 300 mg/day and aspirin 100 mg/day ) maintenance treatment for two years or observation.Primary endpoint was progression free survival (PFS) .Secondary endpoints were overall survival (OS) and safety. Results: From January 2009 to June 2013, 90 patients were enrolled in this study.30 patients were assigned to thalidomide maintenance treatment and 60 to observation as control group. At a median follow-up of 36months, 3-year PFS was superior for treatment group compared with control group in patients with IPI more than 2 (61.0% vs 39.3%,p=0.049 ). 3-year OS was also significant better in treatment group than in control group in patients with IPI more than 2 (66.7% vs 43.3%,p=0.004). Patients with IPI equal to 2 received thalidomide maintenance showed no significant 3-year PFS benefit and 3-year OS benefit (81.5% vs 72.8% ,90% vs 75.4%,p=0.730 and p=0.327 respectively). There was no grade 3 to 4 adverse events and no treatment-related deaths in patients received thalidomide maintenance. Conclusions: Thalidomide as the maintenance treatment improved the PFS and OS with high-risk DLBCL.
Increasing Clinical Faculty Engagement in Problem-Driven Research
Authors: Lilit Garibyan, R. Rox Anderson
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study.
Authors: Marianne Sinn, Torsten Liersch, Klaus Gellert, Helmut Messmann, Wolf O. Bechstein, Dirk Waldschmidt, Lutz Jacobasch, Martin Wilhelm, Bettina M Rau, Robert Grützmann, Arndt Weinmann, Georg Maschmeyer, Uwe Pelzer, Jens Stieler, Jana Kaethe Striefler, B. Michael Ghadimi, Marcus Bahra, Helmut Oettle, Bernd Dörken, Hanno Riess
Journal: Journal of Clinical Oncology (2015)

4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of the EGFR-tyrosinkinase-inhibitor erlotinib (Erlo 100 mg p.o. daily) in combination with Gem (1000 mg/m² i.v. day 1,8,15, q29) for 24 weeks in pts after R0 resection. Methods: In an open-label multicenter design, pts were randomised within 8 weeks after operation to receive GemErlo or Gem; stratified by lymph node involvement, operation techniques, study centre. The primary endpoint was disease-free survival (DFS). The study was planned with a power of 80% at a significance level of 0.05 to detect an improvement of DFS from 14 to 18 months. Secondary objectives were median overall survival (OS) and treatment safety. Kaplan-Meier analyses were performed; survival data for the treatment arms compared using log-rank test. RESULTS: Between April 2008 and July 2013, 219 pts were randomized to GemErlo and 217 to Gem. Pts characteristics are well balanced (GemErlo/Gem): age (median 63/65 years), tumor status (T3/T4 88/86%), nodal status (N pos 64/66%), grading (G3 33/34%). After a median follow up of 41 months (March 2015), 350 events (80%) occurred. Median treatment duration was 22 weeks in both groups. Grade 3/4 toxicities were (GemErlo%/Gem%): rash 7/0.4, diarrhea 5/1, nausea 2/2, fatigue 5/2, hypertension 3/1,GGT 9/9, neutropenia 27/28, thrombopenia 5/2. There was no difference in DFS (median: GemErlo 11.6 months, Gem 11.6 months; HR 0.89, 95%CI 0.72-1.10) or OS (median: GemErlo 24.6 months, Gem 26.5 months; HR 0.90, 95%CI 0.71-1.15). There was no correlation between the grade of rash and an improved DFS in the GemErlo group (median: rash grade 0-1 vs > = grade 2 12.2 vs 11.0 months; HR 0.91, 95%CI 0.66-1.25). OS curves show a late divergence in favour of GemErlo (estimated survival after 2/3/4/5-years: 54/36/31/28% vs 53/33/22/19%). Conclusion: The combination therapy of GemErlo for 24 weeks did not improve DFS or OS. There is a trend in favour of long-term survival in pts treated with GemErlo. Clinical trial information: DRKS00000247.
LC : Clinicopathologic performance for histologic activity of chronic viral hepatitis and Liver fibrosis (초)
Authors: Ha Yan Kang, Won Ae Lee, Hoon Choi, Soung Min Jeon, Sung Hoon Moon, Hyun Duk Shin, Suk Bae Kim, Jeong Eun Shin, Hong Ja Kim, Il Han Song
Journal: Clinical and Molecular Hepatology (2011)
Abstract P310: Predictors of Phase III Enrollment in Participants Completing Phase II Cardiac Rehabilitation in a Large Urban Cardiac Rehabilitation Center
Authors: Harsha V Ganga, Jennifer Jantz, Gaurav Choudhary, Wen-Chih Wu
Journal: Circulation (2016)

Background: Short duration of outpatient Phase II cardiac rehabilitation (CR) program is not sufficient to sustain benefits of CR. Participation in long-term Phase III CR improves exercise capacity and lipoprotein profile. Hypothesis: We examined the factors predicting Phase III CR enrollment in those who have successfully completed Phase II CR in a large urban CR center. Methods: 4714 participants who completed structured 36-session Phase II CR program from the year 2000 to 2014 were included in this retrospective study. Multivariable logistic regression model was used to identify demographic, socio-economic factors predicting Phase III CR enrollment. The Cochran-Armitage test was used to assess temporal trends in Phase III CR enrollment. Results: A total of 901, out of 4714 participants completing Phase II CR, enrolled into Phase III CR. Mean age was 65 years and 31% were females. Univariate predictors include age, race, education, occupation, income, return to work obligation, insurance status, weight loss, depression and anxiety, exercise duration, and metabolic equivalents (METs). On multivariable logistic regression, those with at least college education (Odds Ratio [OR] 1.5,95% confidence interval [CI], 1.07-2), depression (OR,1.5, 95% CI, 1.07-1.96), weight loss (OR, 1.03, 95% CI, 1.01-1.05) and attending more Phase II sessions (OR,1.06, 95% CI, 1.02-1.10) were more likely to enroll whereas those living &gt; 30 minutes from CR center (OR, 0.40, 95% CI, 0.20-0.75), with higher METs (OR,0.93, 95% CI, 0.87-0.99) and exercising longer (OR, 0.96, 95% CI, 0.93-0.99) were less likely to enroll. There is significantly increased temporal trend for Phase III CR enrollment (Z=11.34, P&lt;0.0001). Conclusion: In participants completing Phase II CR, higher education, depression and weight loss predict increased Phase III CR enrollment whereas increased distance from CR center or better exercise capacity predict decreased Phase III CR enrollment.
Clinical Significance of Free Circulating CD4 and CD8 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Authors: Adam Abdool, Francis Giles, Menna Hodge, Susan O’Brien, Michael Keating, Iman Jilani, Hagop Kantarjian, Elihu Estey, Maher Albitar
Journal: Blood (2006)
Orphan Nuclear Receptor TR3 (Nur77) Binds and Converts the Phenotype of Bcl-B, an Anti-Apoptotic Bcl-2-Family Protein Predominantly Expressed in Human Plasma Cells.
Authors: Frederic Luciano, Maryla Krajewska, Xiaokun Zhang, Arnold Satterthwait, John C. Reed
Journal: Blood (2006)